Latest Headlines

  1. NVIDIA BioNeMo Platform Adopted By Life Sciences Leaders To Accelerate AI-Driven Drug Discovery 1/12/2026

    J.P. Morgan Healthcare Conference -- NVIDIA today announced a major expansion of NVIDIA BioNeMo™, an open development platform that enables lab-in-the-loop workflows to develop breakthroughs in AI-driven biology and drug discovery.

  2. Sebela Pharmaceuticals® Announces Submission Of New Drug Application To FDA For Tegoprazan For The Treatment Of Gastroesophageal Reflux Disease 1/12/2026

    Braintree Laboratories, Inc. a part of Sebela Pharmaceuticals® and a leading manufacturer of gastroenterology pharmaceutical products, announced that it submitted a New Drug Application (NDA) on January 9, 2026 to the U.S. Food and Drug Administration (FDA) for tegoprazan, a novel potassium-competitive acid blocker (P-CAB), for the treatment of adults with gastroesophageal reflux disease (GERD).

  3. ConcertAI And Foundation Medicine Integrate Genomic And Clinical Data To Transform Translational Research And Efficient Drug Development 1/12/2026

    ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, and Foundation Medicine, a global, patient-focused precision medicine company, today announced a collaboration to combine their data assets for life sciences research. 

  4. Summit Therapeutics Announces Clinical Trial Collaboration With GSK To Evaluate Ivonescimab In Combination With GSK's B7-H3 Antibody Drug Conjugate (ADC) 1/12/2026

    Summit Therapeutics Inc. today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK’227), GSK’s novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC).

  5. Owkin Advances Frontier Model Development For Biological Artificial Super Intelligence, Accelerated By NVIDIA 1/12/2026

    Owkin, an AI company on a mission to solve the complexity of biology, today announced a collaboration with NVIDIA to enhance OwkinZero, Owkin's biological large reasoning model.

  6. Lantern Pharma Announces Establishing An A.I. Center Of Excellence In India To Industrialize The RADR Platform And Accelerate Global Development Opportunities With Biopharma Companies 1/12/2026

    Lantern Pharma Inc., a pioneer in AI-driven precision oncology and computational therapeutic development, today announced the establishment of an A.I. Center of Excellence and Advanced Agentic Labs in Bengaluru, India.

  7. NVIDIA And Lilly Announce Co-Innovation AI Lab To Reinvent Drug Discovery In The Age Of AI 1/12/2026

    NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry.

  8. insitro To Acquire CombinAbleAI To Complete Its Full Stack, Modality-Agnostic AI Platform For Drug Discovery And Design 1/12/2026

    insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro’s TherML (Therapeutic Machine Learning) platform.

  9. Pierre Fabre Laboratories And Iktos Announce An Integrated AI-Driven Drug Discovery Collaboration In Oncology 1/9/2026

    Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in oncology.

  10. Basilea And Prokaryotics Enter Collaboration To Develop A Novel Broad-Spectrum Antifungal For The Treatment Of Severe Invasive Infections 1/7/2026

    Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, today announced an agreement with Prokaryotics Inc., a privately held US-based biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs.